10/06/2025
🧠 The AI-Mind Project: Strengthening clinical implementation through key partnerships
📢 Following our strategic reorientation towards real-world impact, we’re excited to spotlight the developments on our path to clinical validation of AI-based tools for dementia risk estimation.
🔬 As detailed in our latest blog post, the addition of three new partners: Universitetet i Oslo (UiO) | University of Oslo, Pre Diagnostics AS and Roche, is playing an important role in this transition. These partners bring complementary expertise in biomarker research, EEG analysis and diagnostics to support AI-Mind advancements.
💡 Notably, Pre Diagnostics is conducting blood analyses using the pTau217 biomarker from over 1,000 study participants.
🏥 With these contributions, AI-Mind is moving steadily from development to deployment, with the ultimate goal to empower healthcare professionals with advanced tools for timely diagnosis.
📖 Read the full article: https://www.ai-mind.eu/blog/from-foundation-to-future-ai-mind-strengthens-clinical-implementation/
🌐 Learn more about our partners: https://www.ai-mind.eu/partners/
🔔 Stay informed on our progress and subscribe for updates: https://www.ai-mind.eu/subscribe/
The updated consortium structure, implemented in January 2024, reflects AI-Mind’s evolving priorities. Two industrial partners, Pre Diagnostics AS and Roche, have joined the project, bringing essential capabilities in biomarker development, clinical diagnostics, and technology scaling. With this c...